Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Total Non-Current Liabilities (2016 - 2026)

Standard Biotools has reported Total Non-Current Liabilities over the past 16 years, most recently at $142.2 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 1.93% to $142.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $142.2 million through Dec 2025, up 1.93% year-over-year, with the annual reading at $142.2 million for FY2025, 1.93% up from the prior year.
  • Total Non-Current Liabilities was $142.2 million for Q4 2025 at Standard Biotools, up from $138.8 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $248.3 million in Q1 2022 and troughed at $121.5 million in Q1 2025.
  • The 5-year median for Total Non-Current Liabilities is $162.4 million (2022), against an average of $167.6 million.
  • Year-over-year, Total Non-Current Liabilities soared 37.29% in 2022 and then tumbled 38.48% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $179.7 million in 2021, then dropped by 11.22% to $159.6 million in 2022, then fell by 0.48% to $158.8 million in 2023, then dropped by 12.12% to $139.6 million in 2024, then increased by 1.93% to $142.2 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Total Non-Current Liabilities are $142.2 million (Q4 2025), $138.8 million (Q3 2025), and $131.2 million (Q2 2025).